---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-001256"
form_type: "8-K"
ticker: "NTRB"
cik: "0001676047"
company_name: "NutriBand Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:28:36.528691+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nutriband signs feasibility agreement with Kindeva to develop abuse deterrent fentanyl patch AVERSA

## Summary
- Agreement combines Nutriband's AVERSA abuse deterrent technology with Kindeva's FDA-approved fentanyl patch.
- Partnership focuses on adapting Kindeva's commercial transdermal manufacturing process for AVERSA incorporation.
- Kindeva is a CDMO with 50+ years transdermal experience, formerly 3M Drug Delivery Systems.
- AVERSA technology covered by patents: US notice of allowance, patents in Europe, Japan, Korea, Russia, Mexico, Australia.

## SEC filing metadata
- accession: 0001213900-22-001256
- form_type: 8-K
- ticker: NTRB
- cik: 0001676047
- company_name: NutriBand Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676047/000121390022001256/0001213900-22-001256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676047/000121390022001256/ea153757-8k_nutriband.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-001256
- JSON: https://secwatch.observer/filing/0001213900-22-001256.json
- Plain text: https://secwatch.observer/filing/0001213900-22-001256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.